{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:52:39Z","timestamp":1788558759046,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10\/10 MUDs with antithymocyte globulin (ATG)\u2013based regimens (n\u00a0=\u00a07050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n\u00a0=\u00a0487) in adult patients with hematologic malignancies between 2010 and 2020. Cox proportional hazard-and competing risks regression models were formed to compare the outcomes. Overall survival (OS), Disease-free survival (DFS), and graft-versus-host disease (GVHD)\u2013free and relapse-free survival (GRFS) were superior for 10\/10 MUDs (OS [hazard ratio (HR), 1.27; 95% confidence interval (CI), 1.10-1.47; P\u00a0=\u00a0.001]; DFS [HR, 1.17; CI, 1.02-1.34; P\u00a0=\u00a0.022]; GRFS [HR, 1.34; CI, 1.19-1.50; P\u00a0&amp;lt;\u00a0.001]). The risk of acute GVHD (aGVHD) grade 2 to 4, aGVHD grade 3 to 4, and chronic GVHD (cGVHD) was higher in the PT-CY Haplo group than the 10\/10 MUD group (aGVHD grade 2-4 [HR, 1.46; CI, 1.25-1.71; P\u00a0&amp;lt; .001]; aGVHD grade 3-4 [HR, 1.74; CI, 1.37- 2.20; P\u00a0&amp;lt;\u00a0.001]; cGVHD [HR, 1.30; CI, 1.11-1.51; P\u00a0=\u00a0.001]). A lower incidence of relapse was observed in the PT-CY Haplo group (relapse: HR, 0.83; CI, 0.69-0.99; P\u00a0=\u00a0.038). Unrelated 10\/10 matched transplantation with ATG leads to lower GVHD rates and improved survival rates compared with PT-CY Haplo transplantation in Germany.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013719","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T23:58:39Z","timestamp":1728172719000},"page":"6104-6113","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of haploidentical transplants with PT-CY vs 10\/10 MUD transplants with ATG in Germany"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-8331","authenticated-orcid":false,"given":"Aysenur","family":"Arslan","sequence":"first","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Labuhn","sequence":"additional","affiliation":[{"name":"3Institute of Statistics, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ringhoffer","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine III, St\u00e4dtisches Klinikum Karlsruhe, Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"6Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Germany"},{"name":"7DKMS, Clinical Trials Unit, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[{"name":"9Department of Medicine 2, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"11Department of Medicine A\/Hematology and Oncology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"12Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"13Department of Medicine I\/Hematology and Oncology, Faculty of Medicine, Freiburg Universiy Medical Center, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-8060","authenticated-orcid":false,"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine III, University Clinic Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-9019","authenticated-orcid":false,"given":"Elisa Maria","family":"Amann","sequence":"additional","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Neuchel","sequence":"additional","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Schmid-M\u00f6glich","sequence":"additional","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6943-1577","authenticated-orcid":false,"given":"Sandra","family":"Schmeller","sequence":"additional","affiliation":[{"name":"3Institute of Statistics, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyersmann","sequence":"additional","affiliation":[{"name":"3Institute of Statistics, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6659","authenticated-orcid":false,"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannis","family":"Mytilineos","sequence":"additional","affiliation":[{"name":"18ZKRD-Zentrales Knochenmarkspender-Register f\u00fcr Deutschland, German National Bone Marrow Donor Registry, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"19Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-3169","authenticated-orcid":false,"given":"Daniel","family":"F\u00fcrst","sequence":"additional","affiliation":[{"name":"1Department of Transplantation Immunology, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg \u2013 Hessen, University Hospital Ulm, Ulm, Germany"},{"name":"2Department of Transplantation Immunology, Institute of Transfusion Medicine, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"17","key":"2024121014464794800_bib1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024121014464794800_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024121014464794800_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2014-02-514760","article-title":"Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist","volume":"124","author":"Kekre","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2024121014464794800_bib4","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood-2011-11-354563","article-title":"Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant","volume":"119","author":"Ballen","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2024121014464794800_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2024121014464794800_bib6","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024121014464794800_bib7","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2024121014464794800_bib8","doi-asserted-by":"crossref","first-page":"203.e1","DOI":"10.1016\/j.jtct.2021.12.019","article-title":"Early recovery of myeloid-derived suppressor cells after allogeneic hematopoietic transplant: comparison of post-transplantation cyclophosphamide to standard graft-versus-host disease prophylaxis","volume":"28","author":"Oshrine","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2024121014464794800_bib9","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.bbmt.2016.08.003","article-title":"Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies","volume":"22","author":"Baker","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121014464794800_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024121014464794800_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ajh.25993","article-title":"Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121014464794800_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2024121014464794800_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024121014464794800_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"2024121014464794800_bib15","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2024121014464794800_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2024121014464794800_bib17","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024121014464794800_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024121014464794800_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2024121014464794800_bib20","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024121014464794800_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2024121014464794800_bib22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"issue":"14","key":"2024121014464794800_bib23","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024121014464794800_bib24","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1182\/blood.V99.11.4200","article-title":"The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors","volume":"99","author":"Morishima","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2024121014464794800_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/16078454.2020.1831292","article-title":"Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis","volume":"25","author":"Ma","year":"2020","journal-title":"Hematology"},{"issue":"3","key":"2024121014464794800_bib26","doi-asserted-by":"crossref","first-page":"316.e1","DOI":"10.1016\/j.jtct.2023.10.021","article-title":"HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide versus HLA-matched unrelated donor transplantation for myelodysplastic syndrome","volume":"30","author":"Nakaya","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024121014464794800_bib27","doi-asserted-by":"crossref","first-page":"395.e1","DOI":"10.1016\/j.jtct.2022.04.020","article-title":"Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024121014464794800_bib28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease","volume":"21","author":"Al-Homsi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2024121014464794800_bib29","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2024121014464794800_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024121014464794800_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024121014464794800_bib32","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis","volume":"23","author":"Gagelmann","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121014464794800_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbmt.2015.12.005","article-title":"Observational studies: matching or regression?","volume":"22","author":"Brazauskas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024121014464794800_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-94-015-7983-4_14","volume-title":"Survival Analysis: State. of. the Art","author":"Lee","year":"1992"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6104\/2344956\/blooda_adv-2024-013719-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6104\/2344956\/blooda_adv-2024-013719-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:47:10Z","timestamp":1733842030000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/6104\/518081\/Outcomes-of-haploidentical-transplants-with-PT-CY"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013719","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}